Home › NDC Lookup › RxCUI directory › RxCUI 1248077

Alendronic acid 70 MG Effervescent Oral Tablet — RxCUI 1248077

RxNorm drug concept · Semantic clinical drug
RxCUI 1248077 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1248077
Official nameAlendronic acid 70 MG Effervescent Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asalendronic acid (as alendronate sodium) 70 MG Effervescent Oral Tablet; alendronate sodium 70 MG Effervescent Oral Tablet
FDA products mapped1
Package NDCs mapped2
Reported Medicaid activity (SDUD)13 prescriptions · 1 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Alendronate: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It strengthens bone and lowers fracture risk in osteoporosis. Some products are also used for steroid-induced osteoporosis and Paget's disease of bone. Your pharmacy label shows wh...
  • Take it first thing in the morning with a full glass of plain water, at least 30 minutes before food, drinks or other medicines. Stay upright for at least 30 minutes and until you...
  • Stomach upset, heartburn, nausea, constipation or diarrhea, and some bone or muscle aches can happen. Stop and call your doctor if you have trouble or pain swallowing, chest pain,...
  • What side effects are normal, and when should I call?
📖 Read our full Alendronate guide →

🕸️ Concept Web — How Alendronic acid 70 MG Effervescent Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Alendronic acid 70 MG Effervescent Oral Tablet RxCUI 1248077

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Alendronate 46041
    • Alendronic acid 236083
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Binosto 1248078
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Alendronate Effervescent Oral Tablet 1536440
    • Alendronic acid Effervescent Oral Tablet 2649271
    • Alendronate Oral Product 1367010
    • Alendronic acid Oral Product 2662744
    • Alendronate Effervescent Oral Tablet [Binosto] 1537104
    • Alendronic acid Effervescent Oral Tablet [Binosto] 2657536
    • Binosto Oral Product 1248082
    • Effervescent Oral Tablet 1535727
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Alendronic acid 70 MG SCDC · 904430
  • Alendronate Effervescent Oral Tablet SCDF · 1536440
  • Alendronic acid Effervescent Oral Tablet SCDFP · 2649271
  • Alendronate Oral Product SCDG · 1367010
  • Alendronic acid Oral Product SCDGP · 2662744

Brand-Name Concepts

  • Alendronic acid 70 MG Effervescent Oral Tablet [Binosto] SBD · 1248083
  • Alendronic acid 70 MG [Binosto] SBDC · 1537103
  • Alendronate Effervescent Oral Tablet [Binosto] SBDF · 1537104
  • Alendronic acid Effervescent Oral Tablet [Binosto] SBDFP · 2657536
  • Binosto Oral Product SBDG · 1248082
  • Binosto BN · 1248078

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 1248077 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
70539-0400-04 4 BLISTER PACK in 1 BOX (70539-400-04) / 1 TABLET, EFFERVES... Binosto Radius Health, Inc. 2012-03-12
70539-0400-94 4 BLISTER PACK in 1 BOX (70539-400-94) / 1 TABLET, EFFERVES... Binosto Radius Health, Inc. 2023-03-12
Observed labelers: Radius Health, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$71.6385
Range $71.6385–$71.6385 · middle 50% $71.6385–$71.6385 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.